Summary
PHARMACIE HERBINT has a registered holding activity and consists mainly of financial fixed assets. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €912,519 and a net result of €176,405. Equity has been growing by about 20% per year since 2021. Its solvency ranks better than 64% of 12,775 sector peers (NACE 47, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 03-11-2020 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730and 1 other
- Establishment unit
- 2.309.444.987 1140 Evere, since 03-11-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 16-02-2026
Board and ownership
- HERBINT Sébastien MichelDirector · since 29-10-2020
- Holdings
- Shares in 1 company PHARMACIE LAPERCHE
Financial position
- Gross margin
- €257,825
- ▼ 3.7%
- Turnover
- ≈ €940,000
- estimated
- Profit
- €176,405
- ▼ 4.7%
- Equity
- €912,519
- ▲ 19.1%
- Total assets
- €1.8m
- =
SignalsneutralLatest accounts filed on timeShow the evidence
Checked score
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 5 accounts on average 18 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Registered office moved to Evere
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as PHARMACIE HERBINT: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.5m and €2.2m, founded between 2018 and 2023.
| Company | Total assets | Gross margin |
|---|---|---|
| PHARMACIE HERBINT Evere | €1.8m | €0.3m |
| Varmaca Peer | €2.0m | €0.3m |
| Strybol Iben Pharma Maldegem | €2.2m | €0.2m |
| APR.P.D. Hasselt | €2.1m | €0.2m |
| SEPHALIN Veurne | €1.6m | €0.2m |
| Duchi-Naert Harelbeke | €1.5m | €0.2m |
| K-FARMA Zandhoven | €1.9m | €0.2m |
Key facts about PHARMACIE HERBINT
- What is the company number of PHARMACIE HERBINT?
- The company number of PHARMACIE HERBINT is 0757.764.097. The VAT number is the same number with BE in front: BE 0757.764.097.
- Where is PHARMACIE HERBINT based?
- The registered office is at Louis Piérardlaan 32, 1140 Evere.Company details
- What does PHARMACIE HERBINT do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMACIE HERBINT?
- The legal form of PHARMACIE HERBINT is Private limited company (BV).
- When was PHARMACIE HERBINT founded?
- PHARMACIE HERBINT was founded on 03-11-2020.
- Is PHARMACIE HERBINT still active?
- Yes, PHARMACIE HERBINT is an active enterprise in the KBO register.
- What is the turnover of PHARMACIE HERBINT?
- The turnover in financial year 2025 is ≈ €940,000. This figure is estimated from the gross margin of €257,825 and 47 comparable companies (NACE 477). It probably lies between €730,000 and €1.5m.Financials
- Is PHARMACIE HERBINT profitable?
- In financial year 2025, PHARMACIE HERBINT made a profit of €176,405.
- Where can I find the annual accounts of PHARMACIE HERBINT?
- PHARMACIE HERBINT filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMACIE HERBINT due?
- PHARMACIE HERBINT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.